New techniques improve specificity of CRISPR/Cas9 genome editing tools

Published: Monday, July 20, 2015 - 11:08 in Biology & Nature

Related images
(click to enlarge)

<p><a target="_blank" href="http://online.liebertpub.com/hum"><em>Human Gene Therapy</em></a>, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, <em>Human Gene Therapy</em> presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, <em>Human Gene Therapy Methods</em>, published bimonthly and focused on the application of gene therapy to product testing and development, and <em>Human Gene Therapy Clinical Development</em>, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the <em>Human Gene Therapy</em> website.
&copy;Mary Ann Liebert, Inc., publishers

To overcome the off-target mutations that commonly occur with CRISPR/Cas9 genome editing methods, researchers at Harvard Medical School and Massachusetts General Hospital have developed two strategies that greatly improve the specificity of RNA-guided nucleases for the DNA region targeted to be cut and repaired. A description of these new techniques and their successful use to modify human cancer cells and embryonic stem cells is described in a special issue on genome editing in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website until October 15, 2015. In the special issue led by Guest Editor Feng Zhang, PhD, Broad Institute of MIT and Harvard, and McGovern Institute for Brain Research, MIT (Cambridge, MA), ?Nicolas Wyvekens, Ved Topkar, Cyd Khayter, J. Keith Joung, and Shengdar Tsai present their work in the article "Dimeric CRISPR RNA-Guided FokI-dCas9 Nucleases Directed by Truncated gRNAs for Highly Specific Genome Editing 9." They introduce two new strategies to reduce the off-target effects of current CRISPR genome editing methods: the use of truncated guide RNA molecules (gRNAs), creating shorter binding sites between the gRNAs and targeted DNA regions; and the addition of a FokI domain to the Cas9 protein, resulting in the formation of a nuclease dimer instead of monomer (the RNA-guided FokI-dCas9 Nuclease, or RFN).

Source: Mary Ann Liebert, Inc./Genetic Engineering News

Share

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net